Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807094 | 0.80 | ALDH1A1 (0.44) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL20047186 | 0.78 | LMNA (0.33) | LMNATSHR | |
| SCHEMBL6886372 | 0.77 | LMNA (0.41) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL28379275 | 0.77 | LMNA (0.40) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL20404561 | 0.77 | LMNA (0.40) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2519451 | 0.77 | LMNA (0.36) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL19912633 | 0.77 | LMNA (0.40) | LMNATSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL20658879 | 0.76 | LMNA (0.39) | LMNATSHRKMT2AALDH1A1CA12 | |
| SCHEMBL8481372 | 0.76 | LMNA (0.43) | LMNATSHRKMT2AALDH1A1CA12 | |
| SCHEMBL12921475 | 0.75 | MGLL (0.31) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053907-B1 | SELECTIVE PRODUCTION METHOD FOR D-MANNITOL ALPHA-FORM CRYSTAL USING SPRAY-DRYING METHOD | DAIICHI SANKYO CO LTD (JP) | 2018-08-01 | — | — | EP | claimed |
| US-9918938-B2 | Selective production method for D-mannitol α-form crystal using spray-drying method | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | claimed |
| US-7507400-B2 | Water soluble depilatory having extended shelf life | SPINA THOMAS N | 2009-03-24 | — | — | US | claimed |
| US-20070243240-A9 | Transdermal therapeutic system | WINDT-HANKE FRED | 2007-10-18 | — | — | US | claimed |
| WO-2006099946-A1 | TRANSDERMAL THERAPEUTIC SYSTEM | NEUROBIOTEC GMBH (DE) | 2006-09-28 | — | — | WO | claimed |
| US-20060105030-A1 | Transdermal therapeutic system | AXXONIS PHARMA AG (DE) | 2006-05-18 | — | — | US | claimed |
| US-20030004522-A1 | Water soluble depilatory having extended shelf life | SPINA THOMAS N (US) | 2003-01-02 | — | — | US | claimed |
| CN-119630716-A | Photopolymerization initiator composition, photocurable composition, and process for producing the same Photocurable composition kit and photocurable resin composition | 大阪有机化学工业株式会社 | 2025-03-14 | — | — | CN | disclosed |
| CN-114423902-B | Water-decomposable sheet | 大王制纸株式会社 | 2023-07-18 | — | — | CN | disclosed |
| CN-115151176-A | Wet sheet for cleaning and method for producing the same | 大王制纸株式会社 | 2022-10-04 | — | — | CN | disclosed |
| US-20210171776-A1 | PLATE-LIKE PVD ALUMINUM PIGMENT WITH A PROTECTIVE ENCAPSULATION AND METHOD FOR MANUFACTURING A PLATE-LIKE PVD ALUMINIUM PIGMENT WITH A PROTECTIVE ENCAPSULATION | ECKART GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| EP-3720912-A1 | PLATE-LIKE PVD ALUMINUM PIGMENT WITH A PROTECTIVE ENCAPSULATION AND METHOD FOR MANUFACTURING A PLATE-LIKE PVD ALUMINIUM PIGMENT WITH A PROTECTIVE ENCAPSULATION | ECKART GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| CN-111386318-A | Flake PVD aluminum pigments with protective coating and method for producing flake PVD aluminum pigments with protective coating | 埃卡特有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2006099946-A1 | TRANSDERMAL THERAPEUTIC SYSTEM | NEUROBIOTEC GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060105030-A1 | Transdermal therapeutic system | AXXONIS PHARMA AG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050220855-A1 | Transdermal therapeutic system | AXXONIS PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20050214353-A1 | Transdermal therapeutic system | AXXONIS PHARMA AG (DE) | 2005-09-29 | — | — | US | disclosed |
| US-20050170155-A1 | Image recording media and image recording method | FUJI PHOTO FILM, CO., LTD (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20040219191-A1 | Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means | AXXONIS PHARMA AG (DE) | 2004-11-04 | — | — | US | disclosed |
| US-20040092544-A1 | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states | AXXONIS PHARMA AG (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220855-A1 | Transdermal therapeutic system | TTPA, TXNRD1, TRHDE | LMNA 1549/4885TSHR 505/4885KMT2A 1638/4885 |
| US-20040219191-A1 | Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means | COMT, NTSR1, NTSR2 | LMNA 4401/4885TSHR 126/4885KMT2A 2843/4885 |
| US-20070243240-A9 | Transdermal therapeutic system | TXNRD2, TTPA, TXNRD1 | LMNA 1768/4885TSHR 475/4885KMT2A 1890/4885 |
| US-20040092544-A1 | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states | SLC6A3, SLC6A2, NTSR1 | LMNA 4322/4885TSHR 84/4885KMT2A 3712/4885 |
| US-20050214353-A1 | Transdermal therapeutic system | SLC6A2, PER2, SLC6A3 | LMNA 1491/4885TSHR 115/4885KMT2A 956/4885 |
| US-20060105030-A1 | Transdermal therapeutic system | TXNRD2, TTPA, TXNRD1 | LMNA 1768/4885TSHR 475/4885KMT2A 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.